[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-465398-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-465398-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","longitudinal-comparison-of-calprotectin-and-c-reactive-protein-in-rheumatoid-arthritis-real-world-evidence-across-three-targeted-therapies","Longitudinal Comparison of Calprotectin and C-Reactive Protein in Rheumatoid Arthritis: Real-World Evidence Across Three Targeted Therapies","","Serum calprotectin is a promising inflammation biomarker in rheumatoid arthritis (RA), but real-world longitudinal head-to-head comparisons across targeted therapies are limited. This retrospective cohort evaluated whether calprotectin and C-reactive protein (CRP) track disease activity over time and predict remission in RA patients treated with adalimumab, upadacitinib, or tocilizumab. Calprotectin and CRP were measured at baseline, month 3, and month 6, while DAS28 and CDAI assessed activity. Calprotectin declined significantly after treatment initiation and generally mirrored improvements in disease activity. Overall, CRP outperformed calprotectin for remission, whereas calprotectin performed better with adalimumab or upadacitinib; in tocilizumab-treated patients, both biomarkers showed comparable performance. Results support calprotectin as a treatment-sensitive, complementary biomarker to CRP, especially when CRP reliability is affected by IL-6 blockade.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/longitudinal-comparison-of-calprotectin-and-c-reactive-protein-in-rheumatoid-arthritis-real-world-evidence-across-three-targeted-therapies/465398/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/longitudinal-comparison-of-calprotectin-and-c-reactive-protein-in-rheumatoid-arthritis-real-world-evidence-across-three-targeted-therapies/465398.png","ImageObject",300,407,{"name":42,"@type":43},"\tJames","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-22","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main objective of the study?","Question",{"text":63,"@type":64},"To evaluate how serum calprotectin and CRP change longitudinally and whether they can predict remission in RA patients treated with adalimumab, upadacitinib, or tocilizumab.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were remission and disease activity assessed?",{"text":68,"@type":64},"Disease activity was measured using DAS28 and the Clinical Disease Activity Index (CDAI), and remission was evaluated based on CDAI (≤2.8) for biomarker discrimination.",{"name":70,"@type":61,"acceptedAnswer":71},"How did calprotectin and CRP perform across the different targeted therapies?",{"text":72,"@type":64},"In the overall cohort CRP performed better, among patients receiving adalimumab or upadacitinib calprotectin performed better, and in the tocilizumab group both biomarkers showed similar performance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},465398,1790866015,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nLongitudinal Comparison of Calprotectin and C-Reactive Protein in Rheumatoid Arthritis: Real-World Evidence Across Three Targeted Therapies  \nAngelo Fassio 1, Isotta Galvagni 1, Silvia Sartoris 2,3, Denise Alessandra Cassandrini 2, Federico Aldegheri 1, *, Maurizio Rossini 1, Francesco Pollastri 1, Giovanni Adami 1, Davide Gatti 1, Rosanna Somma 1,  \nMatteo Appoloni 1, Antonio Carletto 1, Vincenzo Bronte 2,3 and Alessandra Arcolaci 2  \nReceived: 30 October 2025  \nRevised: 13 December 2025  \nAccepted: 15 December 2025  \nPublished: 24 December 2025  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Rheumatology Unit, University of Verona, 37126 Verona, Italy; angelo.fassio@aovr.veneto.it (A.F.); [isottagalvagni8@gmail.com](isottagalvagni8@gmail.com) (I.G.); [maurizio.rossini@univr.it](maurizio.rossini@univr.it) (M.R.); [franpollastri@yahoo.it](franpollastri@yahoo.it) (F.P.); [giovanni.adami@univr.it](giovanni.adami@univr.it) (G.A.); [davide.gatti@univr.it](davide.gatti@univr.it) (D.G.); [rosanna.somma20@gmail.com](rosanna.somma20@gmail.com) (R.S.); [appolonimatteo.95@gmail.com](appolonimatteo.95@gmail.com) (M.A.); [antonio.carletto@aovr.veneto.it](antonio.carletto@aovr.veneto.it) (A.C.)  \n2 Immunology Unit, University Hospital of Verona, 37126 Verona, Italy; [silvia.sartoris@univr.it](silvia.sartoris@univr.it) (S.S.); [denisealessandra.cassandrini@aovr.veneto.it](denisealessandra.cassandrini@aovr.veneto.it) (D.A.C.); [vincenzo.bronte@univr.it](vincenzo.bronte@univr.it) (V.B.); [alessandra.arcolaci@aovr.veneto.it](alessandra.arcolaci@aovr.veneto.it) (A.A.)  \n3 Immunology Section, Department of Medicine, University of Verona, 37126 Verona, Italy  \n* Correspondence: [federico.aldegheri@univr.it](federico.aldegheri@univr.it)  \nAbstract  \nBackground/Objectives: Serum calprotectin is a promising biomarker of inflammation in rheumatoid arthritis (RA), yet real-world longitudinal comparisons across different targeted therapies remain limited. We aimed to evaluate the dynamics and remissionpredictive ability of serum calprotectin and C-reactive protein (CRP) in RA patients treated with adalimumab, upadacitinib, or tocilizumab. Methods: In this retrospective cohort study, patients with RA initiating one of the above therapies were included. Serum calprotectin and CRP were measured at baseline, month 3, and month 6 . Disease activity was assessed by DAS28 and Clinical Disease Activity Index (CDAI) . Linear mixed-effects models adjusted for cumulative prednisone dose were used to assess biomarker trends overtime. ROC curve analyses based on CDAI remission (≤2.8) evaluated the discriminative performance of calprotectin and CRP, stratified by treatment subgroups. Results: Sixty patients were enrolled (20 receiving tocilizumab, 20 adalimumab and 20 upadacitinib) . Significant reductions in serum calprotectin, CRP, and DAS28 were observed over time (p \u003C 0.001 for all), independent of treatment group. In the overall cohort including baseline, CRP outperformed calprotectin (AUC 0.739 vs. 0.636; p = 0.044) . Among patients treated with adalimumab or upadacitinib, calprotectin significantly outperformed CRP (AUC 0.929 vs. 0.857; p = 0.049) . In the tocilizumab group, both biomarkers showed similar AUCs (p = 0.888) . Conclusions: Serum calprotectin declined significantly after treatment initiation and outperformed CRP in identifying remission under TNFα and JAK inhibition. It also retained a good performance under IL-6 blockade. These findings support its role asa treatment-sensitive biomarker suggesting a complementary role alongside CRP in RA monitoring, particularly in settings where CRP reliability is pharmacologically suppressed.  \nKeywords: calprotectin; rheumatoid arthritis; biological disease-modifying antirheumatic drugs; C-reactive protein  \n1. Introduction  \nRheumatoid art","cbCaidGWss3xWkea","https://ap.wps.com/l/cbCaidGWss3xWkea","pdf",1587943,11,"English","# Abstract\n## Background/Objectives\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the main objective of the study?\",\"answer\":\"To evaluate how serum calprotectin and CRP change longitudinally and whether they can predict remission in RA patients treated with adalimumab, upadacitinib, or tocilizumab.\"},{\"question\":\"How were remission and disease activity assessed?\",\"answer\":\"Disease activity was measured using DAS28 and the Clinical Disease Activity Index (CDAI), and remission was evaluated based on CDAI (≤2.8) for biomarker discrimination.\"},{\"question\":\"How did calprotectin and CRP perform across the different targeted therapies?\",\"answer\":\"In the overall cohort CRP performed better, among patients receiving adalimumab or upadacitinib calprotectin performed better, and in the tocilizumab group both biomarkers showed similar performance.\"}]","Longitudinal Comparison of Calprotectin and C-Reactive Protein in Rheumatoid Arthritis: Real-World Evidence Across Three Targeted Therapies | PDF",1790769581,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/6bde41cb932d2eaa0d974f726e7dd43e.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/10fc8e1f3dd9c813b1d5bc38c8531652.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/0676d3f72dcea39eb8a6bb0b3be67d48.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/813baf8cb48f2397afbfa91b6e4cd705.webp",980,1385]